Latest Breaking News On - Boys with duchenne muscular - Page 1 : vimarsana.com

Catalyst Pharmaceuticals (CPRX) Announces Publication of Santhera Pharmaceutical s VISION-DMD Vamorolone Study Results in the Peer-Reviewed Journal Neurology

Catalyst Pharmaceuticals (CPRX) Announces Publication of Santhera Pharmaceutical s VISION-DMD Vamorolone Study Results in the Peer-Reviewed Journal Neurology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCatalyst or company nasdaqCatalyst pharmaceuticals incCatalyst pharmaceuticalsSanthera pharmaceuticalVamorolone overBoys with duchenne muscularNorth star ambulatory assessment

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology -February 21, 2024 at 09:03 am EST

Santhera s Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety.

United statesUnited kingdomCatalyst or company nasdaqCatalyst pharmaceuticals incLife science allianceExchange commissionCatalyst pharmaceuticalsHealth canadaStudy reportsWeek treatmentDuchenne muscular dystrophySafety profileSanthera pharmaceuticalVamorolone overBoys with duchenne muscularNorth star ambulatory assessment

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE) in Patients with Duchenne Muscular Dystrophy in Neurology

14.02.2024 - Results from 112 patients with DMD who completed the study confirm maintenance of efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks AGAMREE has shown safety benefits in patients switching from standard of . Seite 1

Switzerland generalUnited kingdomEuropean unionSanthera pharmaceuticalsVamorolone overBoys with duchenne muscularNorth star ambulatory assessmentSanthera pharmaceuticals holding chartAnthera pharmaceuticals holding kursAnthera pharmaceuticals holding aktie

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited statesUnited kingdomEva kaliasDrug administrationSanthera pharmaceuticalsRegulatory agencyLife science allianceEuropean union summary of product characteristicsHead investor relations communicationsAmerica to catalyst pharmaceuticalsEuropean unionEuropean medicines agencySanthera pharmaceuticals holdingAnnounces publicationTolerability data